News | May 20, 2023
Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company is addressing these observations
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Cipla has received 8 inspectional observations in Form 483
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
All claims against the company in the litigation have now been dismissed.
Subscribe To Our Newsletter & Stay Updated
